ResMed NYSE: RMD
ResMed is a global manufacturer of CPAP masks, machines and other products that diagnose, treat or help manage sleep-disordered breathing
Name | ResMed |
Ticker | RMD |
Exchange | NYSE |
Sector | Health Care |
Industry | Respiratory Disorders |
Price | 215.52 |
52W Low/High | 114.34 / 220.59 |
Market cap | 31 B |
1Y Total Return |
33.68%
Strong |
1Y Volatility |
49.10%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ResMed is a global manufacturer of CPAP masks, machines and other products that diagnose, treat or help manage sleep-disordered breathing
Details
Ticker | RMD |
Name | ResMed |
ISIN | US7611521078 |
CUSIP | 761152107 |
Exchange | NYSE |
Sector | Health Care |
Industry | Respiratory Disorders |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | US S&P 500 Index |
Share as of 1/22/21
Close Price | 215.52 |
52W Low/High | 114.34 / 220.59 |
Market cap | 31 B |
1Y Total Return |
33.68%
Strong |
1Y Volatility |
49.10%
Less Risk |
Beta | 0.42 |
PE (trailing) |
46.25
Above Average |
12M Dividends | 1.56 |
Last Dividend Date | 11/10/20 |
Dividend Yield | 0.72% |
Fin. Strength
Net Profit Margin | 22.5% |
Cash from Op. / Cur. Liabilities | 1.33 |
Diluted Earnings / Share | 4.66 |
ROE | 28.4% |
ROIC | 18.4% |
Price / Revenue | 10.4 |
Price / Book | 11.8 |
Price / CF | 40.2 |
Current Ratio | 2.6 |
Cur.Liabilities / Tot.Liabilities | 0.3 |
Financial Leverage | 0.44 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
3,028
|
2,699
|
2,405
|
2,125
|
1,893
|
1,710
|
|
Gross Profit |
1,765
|
1,550
|
1,372
|
1,238
|
1,097
|
1,013
|
|
R&D |
208
|
190
|
157
|
147
|
126
|
112
|
|
EBITDA |
1,022
|
738
|
697
|
576
|
547
|
512
|
|
Operating Income |
855
|
606
|
573
|
444
|
425
|
413
|
|
Net Income exc. Extra |
680
|
419
|
335
|
352
|
346
|
353
|
|
per Share | |||||||
Diluted avg Shares |
146
|
145
|
144
|
143
|
142
|
142
|
|
EPS exc. Extra |
4.66
|
2.89
|
2.32
|
2.47
|
2.45
|
2.47
|
|
Dividend |
1.56
|
1.50
|
1.42
|
1.34
|
1.23
|
1.14
|
|
Div. Yield (an.) |
0.91%
|
1.11%
|
1.23%
|
1.74%
|
1.90%
|
2.24%
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
4,621
|
4,155
|
3,068
|
3,490
|
3,322
|
2,255
|
|
Cash, Eq & Invt ShortTerm |
421
|
172
|
230
|
811
|
782
|
822
|
|
Total Current Assets |
1,543
|
1,161
|
1,088
|
1,658
|
1,475
|
1,533
|
|
Total Non-Current Assets |
3,078
|
2,993
|
1,979
|
1,832
|
1,847
|
722
|
|
Intangibles |
2,333
|
2,353
|
1,434
|
1,323
|
1,352
|
305
|
|
Total Liabilities |
1,942
|
2,037
|
1,167
|
1,440
|
1,550
|
794
|
|
Total Current Liabilities |
591
|
550
|
421
|
352
|
621
|
257
|
|
Long Term Debt |
1,351
|
1,487
|
746
|
1,089
|
929
|
537
|
|
Shareholder equity |
2,679
|
2,117
|
1,900
|
2,050
|
1,773
|
1,461
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
784
|
573
|
459
|
422
|
510
|
421
|
|
Depreciation |
187
|
164
|
121
|
114
|
96
|
73
|
|
Cash from Investing |
-169
|
-961
|
-235
|
-84
|
-1,076
|
-164
|
|
Capex |
86
|
78
|
60
|
64
|
57
|
58
|
|
Cash from Financing |
-392
|
336
|
-776
|
-329
|
468
|
-147
|
|
Stock Issued |
44
|
38
|
-38
|
36
|
-15
|
-133
|
|
Debt (LT) Issued |
-165
|
542
|
-519
|
-155
|
656
|
123
|
|
Free Cash Flow |
449
|
627
|
600
|
-22
|
711
|
288
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
22.5%
|
15.5%
|
13.9%
|
16.6%
|
18.3%
|
20.6%
|
|
NCFO / Op.Income |
91.6%
|
94.6%
|
80.1%
|
95.0%
|
119.9%
|
102.1%
|
|
Current Ratio |
2.6
|
2.1
|
2.6
|
4.7
|
2.4
|
6.0
|
|
Financial Leverage D/E |
0.44
|
0.62
|
0.28
|
0.50
|
0.66
|
0.34
|
|
Return on Capital Avg |
18.4%
|
15.7%
|
12.2%
|
17.6%
|
23.2%
|
30.4%
|
|
Return on Shareholder Equity |
28.4%
|
20.9%
|
17.0%
|
18.4%
|
21.4%
|
22.6%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available